SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD shares are gaining momentum as the company outlines an aggressive AI expansion strategy, with management projecting a massive total addressable market by 2030 and significant growth in data center revenue. Traders are actively debating the sustainability of this rally, with bulls citing robust AI demand and new product launches, while some skeptics argue the valuation is overextended and driven by market hype.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta is trending as investors react to the launch of 'Muse,' a personal AI agent designed to perform real-world tasks, alongside recent comments from Mark Zuckerberg regarding Threads' growth relative to X. While the AI rollout sparked debate about the potential return on massive capital expenditures, the stock has seen volatile trading driven by algorithmic activity and conflicting sentiments over the company's long-term AI strategy.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The community conversation is fragmented, with the most dominant themes centering on geopolitical instability in the Middle East following U.S.-Iran skirmishes, rising oil prices approaching $100 per barrel, and persistent concerns over inflationary pressures. Traders are actively debating whether these factors signal an impending market correction or a continuation of the bullish trend, with many expressing frustration over stagnant price action and algorithmic manipulation.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Traders are closely monitoring Apple's upcoming product launch event, with sentiment split between excitement over the potential debut of a foldable iPhone and skepticism regarding the company's innovation and production capacity. Discussion is heavily focused on whether the event will trigger a "sell the news" decline or a momentum-driven rally, while some market participants are analyzing option flow and macro correlations to position for post-launch volatility.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending following the conditional approval of its 2-gigawatt Sweetwater Hub as Base Load in the ERCOT Batch Zero grid-connection process. While traders are expressing strong bullish sentiment and discussing potential short squeezes, some community members urge caution and profit-taking, noting that the status remains conditional and subject to further approvals.

Magnite, Inc. provides a technology solution to automate the purchase and sale of digital advertising inventory for buyers and sellers. It features applications and services for digital advertising sellers including websites, mobile applications, and other digital media properties. The company was founded by Frank Addante, Duc Chau, Craig Roah, Julie Mattern and Brian D. Baumgart on April 20, 2007 and is headquartered in New York, NY.

Magnite Inc

Magnite is attracting investor attention due to the ongoing growth of its Connected TV (CTV) business and positive momentum from the digital advertising sector. Market participants are also focused on the potential financial upside from anticipated court-ordered behavioral remedies in the Google ad-tech antitrust litigation, which is expected to create a more competitive environment for independent platforms.

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc

AstraZeneca PLC

AstraZeneca is trending following FDA Priority Review acceptance for its hypertension drug baxdrostat, with a decision anticipated in the second quarter of 2026. Investors are also focused on the company's recent strategic collaboration with CSPC Pharmaceuticals to expand its obesity pipeline and its official listing on the New York Stock Exchange.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending due to heightened speculation regarding an imminent buyout and the company's progress toward a Q4 2026 NDA submission for its wet AMD treatment, Axpaxli. Investors are closely monitoring the competitive landscape following a trial setback for competitor Eyepoint Pharmaceuticals, which has fueled debate over the dominance of TKI-based retinal therapies.

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

Chainlink is seeing heightened discussion around its role as critical infrastructure for real-world asset (RWA) tokenization and institutional financial partnerships, despite ongoing community frustration regarding stagnant price action. Traders remain divided between those maintaining long-term conviction in the project's utility and those concerned about lackluster price performance compared to broader market moves.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology Group is experiencing high volatility and significant selling pressure following its recent earnings, with traders debating whether the decline is a temporary overreaction or a structural shift based on concerns about valuation, margin pressure, and customer concentration. While some investors view current price levels as a buying opportunity based on strong growth prospects in AI connectivity, many traders are closely watching technical support levels for signs of a potential reversal or further downside gap-filling.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?

Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Amarin (AMRN) have performed compared to their sector so far this year.

All You Need to Know About Acumen Pharmaceuticals (ABOS) Rating Upgrade to Buy

Acumen Pharmaceuticals (ABOS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Are Medical Stocks Lagging  Acumen Pharmaceuticals (ABOS) This Year?

Acumen Pharmaceuticals (ABOS) Expected to Announce Quarterly Earnings on Tuesday

Acumen Pharmaceuticals (NASDAQ:ABOS) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-acumen-pharmaceuticals-inc-stock...

Short Interest in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Increases By 46.4%

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) was the recipient of a significant increase in short interest in April. As of April 15th, there was short interest totaling 1,545,029 shares, an increase of 46.4% from the March 31st total of 1,055,415 shares. Approximately 2.4% of the...

Acumen Pharmaceuticals (NASDAQ:ABOS) Trading 0.7% Higher   - Still a Buy?

Acumen Pharmaceuticals (NASDAQ:ABOS) Shares Up 0.7% - Here's Why...

Acumen Pharmaceuticals (ABOS) Loses 33.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Acumen Pharmaceuticals (ABOS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Here is how Acumen Pharmaceuticals, Inc. (ABOS) and ADC Therapeutics SA (ADCT) have performed compared to their sector so far this year.

Acumen Pharmaceuticals (NASDAQ:ABOS) Rating Increased to Hold at Wall Street Zen

Wall Street Zen raised Acumen Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Sunday...

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) has been given an average rating of "Moderate Buy" by the six brokerages that are currently covering the stock, Marketbeat Ratings...

Reported GAAP EPS of -$0.45 up 33.82% YoY

Acumen Pharmaceuticals remains a pre-revenue company reporting consistent quarterly net losses, while facing structural risks from macroeconomic volatility and the high uncertainty inherent in its clinical-stage drug development pipeline.

Acumen Pharmaceuticals is advancing its pipeline with two novel Enhanced Brain Delivery candidates and anticipates critical Phase 2 topline results for its lead product candidate, sabirnetug, in late 2026.

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages and develops medicines and diagnostics for Alzheimer's disease. The company was founded by William L. Klein, Grant A. Krafft, and Caleb Finch in 1996 and is headquartered in Newton, MA.

Acumen Pharmaceuticals Inc

Neutral Sentiment

Yes, hike is locked in

No, inflation data still matters more

Fed stays on hold anyway

Too early to tell

August nonfarm payrolls surged by 162,000, nearly triple the 53,000-56,000 consensus estimate and the strongest monthly gain since March, while unemployment held steady at 4.1%, adding fuel to the case for a Federal Reserve rate hike at its September meeting. Does this jobs report cement a September rate hike? Vote and explain your reasoning in the comments.

August nonfarm payrolls surged 162,000, nearly triple estimates, while unemployment held at 4.1%. Does this cement a September rate hike?

Current Price	$3.16
Prev Close	$3.18
Open	$3.14
Dividend Yield	0.00%
50-Day Moving Average	$2.60
Beta	1.58
Avg. Volume	354,522.87
PE Ratio	-1.94

52-Week High	$3.60
52-Week Low	$1.21
Market Capitalization	$229.97M
EPS (Annual)	-$2.00
Price to Book	3.99
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

ABOS Fundamentals